vs
Orthofix Medical Inc.（OFIX）与WisdomTree, Inc.（WT）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是WisdomTree, Inc.的1.4倍（$219.9M vs $159.5M），WisdomTree, Inc.净利率更高（25.5% vs -1.0%，领先26.5%），WisdomTree, Inc.同比增速更快（47.5% vs 2.0%），过去两年WisdomTree, Inc.的营收复合增速更高（22.1% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
WisdomTree, Inc.是总部位于纽约的全球ETF（交易型开放式指数基金）及交易所交易产品发行方与资产管理机构，2006年6月推出首批ETF产品，目前是美国主流ETF供应商之一。其发行的ETF覆盖全球不同资产类别与地区市场，产品线涵盖美国及国际股票、货币、固定收益及另类投资等品类。
OFIX vs WT — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$159.5M
营收增速更快
WT
高出45.6%
2.0%
净利率更高
WT
高出26.5%
-1.0%
两年增速更快
WT
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $159.5M |
| 净利润 | $-2.2M | $40.6M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 37.2% |
| 净利率 | -1.0% | 25.5% |
| 营收同比 | 2.0% | 47.5% |
| 净利润同比 | 92.4% | 76.4% |
| 每股收益（稀释后） | $-0.05 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXWT
| Q1 26 | — | $159.5M | ||
| Q4 25 | $219.9M | $147.4M | ||
| Q3 25 | $205.6M | $125.6M | ||
| Q2 25 | $203.1M | $112.6M | ||
| Q1 25 | $193.6M | $108.1M | ||
| Q4 24 | $215.7M | $110.7M | ||
| Q3 24 | $196.6M | $113.2M | ||
| Q2 24 | $198.6M | $107.0M |
净利润OFIXWT
| Q1 26 | — | $40.6M | ||
| Q4 25 | $-2.2M | $40.0M | ||
| Q3 25 | $-22.8M | $19.7M | ||
| Q2 25 | $-14.1M | $24.8M | ||
| Q1 25 | $-53.1M | $24.6M | ||
| Q4 24 | $-29.1M | $27.3M | ||
| Q3 24 | $-27.4M | $-4.5M | ||
| Q2 24 | $-33.4M | $21.8M |
毛利率OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXWT
| Q1 26 | — | 37.2% | ||
| Q4 25 | 0.2% | 40.5% | ||
| Q3 25 | -8.3% | 36.3% | ||
| Q2 25 | -7.9% | 30.8% | ||
| Q1 25 | -25.2% | 31.6% | ||
| Q4 24 | -5.3% | 31.7% | ||
| Q3 24 | -9.6% | 36.0% | ||
| Q2 24 | -12.5% | 31.3% |
净利率OFIXWT
| Q1 26 | — | 25.5% | ||
| Q4 25 | -1.0% | 27.1% | ||
| Q3 25 | -11.1% | 15.7% | ||
| Q2 25 | -6.9% | 22.0% | ||
| Q1 25 | -27.4% | 22.8% | ||
| Q4 24 | -13.5% | 24.7% | ||
| Q3 24 | -13.9% | -4.0% | ||
| Q2 24 | -16.8% | 20.3% |
每股收益（稀释后）OFIXWT
| Q1 26 | — | $0.28 | ||
| Q4 25 | $-0.05 | $0.28 | ||
| Q3 25 | $-0.57 | $0.13 | ||
| Q2 25 | $-0.36 | $0.17 | ||
| Q1 25 | $-1.35 | $0.17 | ||
| Q4 24 | $-0.76 | $0.20 | ||
| Q3 24 | $-0.71 | $-0.13 | ||
| Q2 24 | $-0.88 | $0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | — |
| 总资产 | $850.6M | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | $132.5M |
总债务OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — |
股东权益OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | $450.0M | $413.7M | ||
| Q3 25 | $442.5M | $373.4M | ||
| Q2 25 | $458.3M | $445.1M | ||
| Q1 25 | $458.3M | $415.6M | ||
| Q4 24 | $503.1M | $400.0M | ||
| Q3 24 | $525.9M | $374.9M | ||
| Q2 24 | $546.0M | $445.6M |
总资产OFIXWT
| Q1 26 | — | $1.8B | ||
| Q4 25 | $850.6M | $1.5B | ||
| Q3 25 | $832.6M | $1.4B | ||
| Q2 25 | $837.2M | $1.1B | ||
| Q1 25 | $823.1M | $1.0B | ||
| Q4 24 | $893.3M | $1.0B | ||
| Q3 24 | $867.9M | $1.0B | ||
| Q2 24 | $882.0M | $964.1M |
负债/权益比OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $18.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | 0.44× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXWT
| Q1 26 | — | $18.0M | ||
| Q4 25 | $27.7M | $147.9M | ||
| Q3 25 | $12.4M | $48.1M | ||
| Q2 25 | $11.6M | $38.8M | ||
| Q1 25 | $-18.4M | $6.4M | ||
| Q4 24 | $23.7M | $113.5M | ||
| Q3 24 | $11.7M | $47.7M | ||
| Q2 24 | $9.0M | $32.2M |
自由现金流OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $147.7M | ||
| Q3 25 | $2.5M | $48.0M | ||
| Q2 25 | $4.5M | $38.7M | ||
| Q1 25 | $-25.1M | $6.3M | ||
| Q4 24 | $15.2M | $113.3M | ||
| Q3 24 | $6.3M | $47.7M | ||
| Q2 24 | $-360.0K | $32.2M |
自由现金流率OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 100.2% | ||
| Q3 25 | 1.2% | 38.2% | ||
| Q2 25 | 2.2% | 34.4% | ||
| Q1 25 | -13.0% | 5.9% | ||
| Q4 24 | 7.0% | 102.4% | ||
| Q3 24 | 3.2% | 42.1% | ||
| Q2 24 | -0.2% | 30.1% |
资本支出强度OFIXWT
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 0.1% | ||
| Q3 25 | 4.8% | 0.0% | ||
| Q2 25 | 3.5% | 0.1% | ||
| Q1 25 | 3.5% | 0.0% | ||
| Q4 24 | 4.0% | 0.1% | ||
| Q3 24 | 2.7% | 0.0% | ||
| Q2 24 | 4.7% | 0.0% |
现金转化率OFIXWT
| Q1 26 | — | 0.44× | ||
| Q4 25 | — | 3.70× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 0.26× | ||
| Q4 24 | — | 4.15× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
WT
| Advisory fees | $134.9M | 85% |
| Other | $6.1M | 4% |
| Third-party distribution fees | $5.8M | 4% |
| Management fees | $5.2M | 3% |
| Sales and business development | $4.2M | 3% |
| Professional fees | $3.3M | 2% |
